'AIIMS Bibinagar fully operational, secured Rs 64 cr in research grants': Union Health Minister JP Nadda
Hyderabad (Telangana) [India], July 9 (ANI): Union Health Minister JP Nadda on Thursday at AIIMS Bibinagar in Telangana, made with an investment of over Rs 1,100 crore, has become fully operational…
Read the full articleYou might also wanna read
UK Quantum Biomedical Hub Awarded £902,000 for Clinical Sensing and Imaging Hardware Development
The UK National Quantum Biomedical Research Hub (Q-BIOMED) has been awarded £902,000 ($1.2 million USD) from the Engineering and Physical Sc
iq.fp2.dev·1mo ago
Manipal Health gets Sebi nod for Rs 8,000-crore IPO
India's IPO pipeline is gaining momentum with significant upcoming public issues. The National Stock Exchange is planning a substantial Rs 3
UK opens £600m funding call to expand biomedical research centre network
£600m in funding is being allocated for an expansion in the network of biomedical research centres, a pillar of the UK's life sciences strat
pharmaphorum.com·1mo ago
Canada invests $100M from AI strategy to expand Ontario health data project Vital nationwide
Funding for Vital program, borne from successful Gemini initiative, aims to improve quality of data available to researchers
theglobeandmail.com·1mo agoCanada invests $100M from AI strategy to expand Ontario health data project Vital nationwide
Funding for Vital program, borne from successful Gemini initiative, aims to improve quality of data available to researchers
theglobeandmail.com·1mo ago
NIHR awards £8.1 million to AI projects including Oxford studies to reduce NHS waiting times
Two studies have received funding from the National Institute for Health and Care Research as part of an £8million initiative to support AI.
digitalhealth.net·14d ago
AustralianSuper commits AU$500 million more to India's NIIF, PM Modi calls it vote of confidence
New Delhi: AustralianSuper, Australia's largest pension fund, will invest an additional AU$500 million in India's National Investment and In
Comments
Sign in to join the conversation.
No comments yet. Be the first.